Several Companies

 
News Articles for Several Companies top ^
Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And Venereology investment picks
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate --
Sign-up for AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease investment picks
Celgene Corporation (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
Sign-up for Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis investment picks
Dupilumab Demonstrated Improvement in Lung Function, Reductions of Severe Exacerbations TARRYTOWN, N.Y. and PARIS , Nov.
Sign-up for Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma investment picks
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS , Dec.
Sign-up for Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis investment picks
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced top-line results from a Phase 2 study of its lead drug candidate, EBI-005, in patients with moderate to severe allergic conjunctivitis.
Sign-up for Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis investment picks
2014/11/14
ECA Group, subsidiary of Groupe Gorgé, has just won a major contract to supply naval simulators to the Navy of an Asian country.
Sign-up for Groupe Gorgé Announces the Sale of Several Naval Simulators to a Major Asian Navy investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for Revolade™ (eltrombopag), seeking an additional indication for the treatment of adult patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). SAA is a rare disorder in which the bone marrow fails to make enough new blood cells.
Sign-up for Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag) investment picks
Brodalumab Meets All Primary and All Key Secondary Endpoints Meets Primary Endpoint of Superiority to Stelara® (ustekinumab) in Achieving Total Skin Clearance (PASI 100) Meets Co-Primary Endpoints Against Placebo THOUSAND OAKS, Calif.
Sign-up for Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo Three Pivotal Studies Form the Basis for Global Regulatory Filings, Planned In 2015 THOUSAND OAKS, Calif.
Sign-up for Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
Primary Efficacy Analysis Demonstrates Clinical Equivalence First Phase 3 Data From Amgen's Biosimilars Program THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from additional efficacy and safety analyses of OTEZLA® (apremilast) from the ESTEEM phase III clinical trial program were released at the 23 rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam.
Sign-up for New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis investment picks
NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of results from a DPNCheck ® study conducted at the Diabetes Research Unit of the Ipswich Hospital NHS Trust in the United Kingdom.
Sign-up for NeuroMetrix Reports Publication of Study Demonstrating that DPNCheck is Effective at Detecting Diabetic Peripheral Neuropathy at all Stages of Severity investment picks
- IDEXX selects UPS to support its US all-direct product distribution capability, providing IDEXX a cost effective, logistics solution for the entire continental US - IDEXX opens significantly expanded US direct customer sales center, offers free shipping and next day delivery for IDEXX direct orders; on track for 100% direct order and fulfillment capability over the course of Q4 - Strong business growth momentum continues in the US Companion Animal Group, reflected in continued strong veterinary diagnostic instrument placements in Q3 - Company announces expectation for earlier reduction of distributor inventories and reduced transitional impacts WESTBROOK, Maine , Oct.
Sign-up for IDEXX Announces Several Milestones in its US All-Direct CAG Distribution Strategy investment picks
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that patient-reported health outcomes data for OTEZLA ® (apremilast) were presented at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam.
Sign-up for Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis investment picks
2014/10/21
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G024123-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/10/17/11G024123/a5c66d64e8f41f6d_org-1368949126.jpg VALENCIA, CA--(Marketwired - October 21, 2014) - PDC Healthcare , the global leader of innovative identification solutions, will unveil its expanded product offering for blood transfusion patient identification at the 2014 AABB Annual Meeting, from October 25 to 28, at the Pennsylvania Convention Center.
Sign-up for PDC Healthcare to Launch Several New Blood Bank ID Solutions That Improve Patient Safety & Efficiency at the 2014 AABB Annual Meeting investment picks
2014/10/27
CHARLOTTE, N.C. , Oct.
Sign-up for Newest Virginia-class submarine commissioned bears several systems from UTC Aerospace Systems investment picks
FORT WORTH, Texas , Nov.
Sign-up for Basic Energy Services To Present At Several Investor Conferences During November investment picks
2014/11/7
By Michael Calia Sprint Corp.
Sign-up for Sprint to take additional $105 million charge on severance costs investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Several Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Seven Companies  |  Next: Shale Assets